Skip to main content

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Terminated · Phase 2 · NCT06220669

Conditions: Multiple Sclerosis

At a glance

Research payments reported, 2025
$677,864
U.S. investigators named
10
Sites paid
14
Planned or actual enrollment
63

About the trial

Sponsor
Eli Lilly and Company
Tested
LY3541860 (drug), Placebo (drug)
Dates
Started 2024-03-19; completion 2026-07-13
Results posted
Not yet

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.

From ClinicalTrials.gov, last updated 2026-09-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $677,864 in research payments for this study in 2025 (26 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Consultants in Neurology $247,432
  • Panhandle Reaearch and Medical $85,796
  • Conquest Research LLC $78,455
  • Univ of South Florida Rsrch Foundation $68,337
  • Infinite Research Group LLC $59,012
  • Prolato Research LLC $56,821
  • Anesc Research $26,765
  • Sharlin Health Neuroscience Research Center $17,147
  • $15,655
  • Interspond LLC $9,583
  • Advanced Neuro Research Center $4,254
  • Healthcare Innovations Institute LLC $4,237
  • Sibyl Wray Neurology PC $3,200
  • Sharlin Health and Neurology LLC $1,146
  • Usf Health Byrd Alzheimer's $24

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.